Comparison between Nicorandil and Magnesium as an Adjunct Cardioprotective Agent to Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction

Circulation Journal

Volumn 68, Issue 3, 2004, Pages 192-197

  Nameki, Mizuo ^a   Ishibashi, Iwao ^a   Miyazaki, Yoshiya ^a   Sakai, Yoshiaki ^a   Namikawa, Susumu ^a   Kuriyama, Nehiro ^a   Komiyama, Nobuyuki ^a   Tsunoda, Kouichi ^a   Masuda, Yoshiaki ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myocardial infarction; Magnesium; Nicorandil; Reperfusion therapy

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; MAGNESIUM SULFATE; NICORANDIL; NITRATE; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICULOGRAPHY; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; INTRACORONARY INFUSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOTONIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAGNESIUM; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; NICORANDIL; RISK FACTORS;

EID: 12144287828     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.192     Document Type: Article

References (38)

1. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 1985; 312: 932-936.
2. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.
3. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993; 21: 537-545.
4. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989; 63: 18J-24J.
5. Iseri LF, French JH. Magnesium: Nature's physiologic calcium blocker. Am Heart J 1984; 108: 188-193.
6. Lamping KA, Christensen CW, Pelc LR, Warltier DC, Gross GJ. Effect of nicorandil and nifedipine on protection of ischemic myocardium. J Cardiovasc Pharmacol 1984; 6: 536-542.
7. Mizunuma T, Nithipatikon K, Gross GJ. Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog. Cardiovasc Res 1995; 29: 482-489.
8. Christensen CW, Rieder MA, Silverstein EL, Gencheff NE. Magnesium sulfate reduces myocardial infarct size when administered prior to but not after coronary reperfusion in a canine model. Circulation 1995; 92: 2617-2621.
9. Herzog WR, Schlossberg ML, MacMurdy KS, Edenbaum LR, Gerber MJ, Vogel RA, et al. Timing of magnesium therapy affects experimental infarct size. Circulation 1995; 92: 2622-2626.
10. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. Am J Coll Cardiol 1999; 33: 654-660.
11. Sakata Y, Kodama K, Komamura K, Lim YJ, Ishikura F, Hirayama A, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and inprovement in patients with acute myocardial infarction. Am Heart J 1997; 133: 616-621.
12. Kobayashi Y, Goto Y, Daikoku S, Itoh A, Miyazaki S, Ohshima S, et al. Cardioprotective effect of intravenous nicorandil in patients with successful reperfusion for acute myocardial infarction. Jpn Circ J 1998; 62: 183-189.
13. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: Result of the second Leicester Intravenous Magnesium Intervation Trial (LIMIT-2). Lancet 1992; 339: 1553-1558.
14. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomized factorial trial assessing early oral captril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
15. Shechter M, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 1995; 75: 321-323.
16. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI Frame Count: A quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-888.
17. Sheehan FH, Stewart DK, Dodge HT, Mitten S, Bolson EL, Brown BG. Viability in the measurement of regional left ventricular wall motion from contrast angiograms. Circulation 1983; 68: 550-559.
18. Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schofer J, Woo HW. Advantages and applications of the centerline method for characterizing regional ventricular function. Circulation 1986; 74: 293-305.
19. Opie LH. Reperfusion injury and its pharmacologic modification. Circulation 1989; 80: 1049-1062.
20. Ambrosio G, Tritto I. Reperfusion injury: Experimental evidence and clinical implications. Am Heart J 1999; 138: S69-S75.
21. Theroux P, Gregoire J, Chin C, Pelletier G, de Guise P, Juneau M. Intravenous diltiazem in acute myocardial infarction: Diltiazem as adjunctive therapy to activase (DATA) trial. J Am Coll Cardiol 1998; 32: 620-628.
22. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction: Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001; 38: 1644-1650.
23. Rusnak JM, Kopecky SL, Clements IP, Gibbons RJ, Holland AE, Peterman HS, et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am J Cardiol 2001; 88: 482-487.
24. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-2701.
25. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial. J Am Coll Cardiol 1999; 34: 1711-1720.
26. Sugimoto K, Ito H, Iwakura K, Ikushima M, Kato A, Kimura R, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003; 67: 295-300.
27. Isobe N, Oshaima S, Taniguchi K, Hoshizaki H, Adachi H, Toyama T, et al. Nicorandil infusion leads to good recovery from ischemia of left ventricular regional work in comparison with nitroglycerin. Circ J 2002; 66: 943-948.
28. Baxter GF, Sumeray MS, Walker JM. Infarct size and magnesium: Insights into LIMIT-2 and ISIS-4 from experimental studies. Lancet 1996; 348: 1424-1426.
29. Antman EM. Magnesium in acute MI. Circulation 1995; 92: 2367-2372.
30. Pieper GM, Gross GJ. Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil. Cardiovasc Drug Ther 1992; 6: 225-232.
31. Garcia LA, Dejong SC, Martin SM, Smith RS, Buettner GR, Kerber RE. Magnesium reduces free radicals in an in vivo coronary occlusion-reperfusion model. J Am Coll Cardiol 1998; 32: 536-539.
32. Hearse DJ. Activation of ATP-sensitive potassium channels: A novel phamacological approach to myocardial protection? Cardiovasc Res 1995; 30: 1-17.
33. Rabbani LE, Antman EM. The role of magnesium therapy in acute myocardial infarction. Clin Cardiol 1996; 19: 841-844.
34. Garlid K, Paucek P, Yarov-Yarovoy V. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K channels: Possible mechanism of cardioprotection. Circ Res 1997; 81: 1072-1082.
35. Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K channels and myocardial preconditioning. Circ Res 1999; 84: 973-979.
36. Dairaku Y, Miura T, Harada N, Kimura M, Okamura T, Iwamoto H, et al. Effect of ischemic preconditioning and mitochondrial KATP channel openers on chronic left ventricular remodeling in the ischemic-reperfused rat heart. Circ J 2002; 66: 411-415.
37. Sato T, Sasaki N, O'Rourke B, Marban E. Nicorandil, a potent cardioprotective agent, acts by opening mitocondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000; 35: 514-518.
38. The IONA Study group. Effect of nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet 2002; 359: 1269-1275.